Scarica l'app Stockscreener
0.8371
2.72%
0.0222
Dopo l'orario di chiusura:
.82
-0.0171
-2.04%
Precedente Chiudi:
$0.8149
Aprire:
$0.789
Volume 24 ore:
382.11K
Relative Volume:
0.19
Capitalizzazione di mercato:
$4.59M
Reddito:
-
Utile/perdita netta:
$-8.72M
Rapporto P/E:
-0.1526
EPS:
-5.4871
Flusso di cassa netto:
$-5.47M
1 W Prestazione:
-19.51%
1M Prestazione:
-41.46%
6M Prestazione:
-38.90%
1 anno Prestazione:
-70.10%
Intervallo 1D:
$0.7694
$0.87
Intervallo di 1 settimana:
$0.7449
$1.5399
Portata 52W:
$0.7449
$3.61
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.8371 | 4.47M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Iniziato | Craig Hallum | Buy |
| 2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-08-02 | Reiterato | Maxim Group | Buy |
| 2018-07-13 | Iniziato | Stifel | Buy |
| 2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
| 2018-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Iniziato | ROTH Capital | Buy |
| 2017-08-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Reiterato | Maxim Group | Buy |
| 2016-08-01 | Reiterato | Maxim Group | Buy |
| 2016-07-06 | Ripresa | ROTH Capital | Buy |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
What drives Galmed Pharmaceuticals Ltd stock priceAutomated Trading Signals & Free Unlock Hidden Market Opportunities - earlytimes.in
Key metrics from Galmed Pharmaceuticals Ltd.’s quarterly dataJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Can swing trading help recover from Galmed Pharmaceuticals Ltd. lossesTrade Ideas & Daily Profit Maximizing Tips - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock resilient in recession scenarios - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investingMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock suitable for passive index fundsWeekly Trading Summary & Verified Momentum Watchlists - newser.com
Why Galmed Pharmaceuticals Ltd. stock attracts global investorsWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study - MSN
How buyback programs support Galmed Pharmaceuticals Ltd. (GPH) stock2025 Macro Impact & AI Enhanced Trading Alerts - newser.com
Views of Wall Street’s Leading Experts on Galmed Pharmaceuticals Ltd - Setenews
Galmed Pharmaceuticals Reports Promising Results from Aramchol Meglumine Study - TipRanks
Galmed announces meaningful top line results from AM-001 study of Aramchol meglumine - MarketScreener
Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan
Galmed reports 3-drug combo enhances cancer treatment efficacy By Investing.com - Investing.com Canada
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth eraTrade Volume Summary & Fast Moving Market Watchlists - newser.com
Is It Time to Reconsider Galmed Stock? - StocksToTrade
Galmed Pharmaceuticals Ltd. (GLMD) Stock: Soars 10.85% Following Breakthrough Cancer Treatment Results - parameter.io
NASDAQ:GLMD News 17 November 2025 - ts2.tech
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025 - ts2.tech
Galmed stock soars after promising cancer treatment research results By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals: Is It A Turnaround Story? - timothysykes.com
Galmed stock soars after promising cancer treatment research results - Investing.com
Galmed reports 3-drug combo enhances cancer treatment efficacy - Investing.com
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - WV News
How Galmed Pharmaceuticals Ltd. stock performs after earningsBreakout Watch & Risk Adjusted Swing Trade Ideas - newser.com
How Galmed Pharmaceuticals Ltd. stock reacts to inflationary pressuresTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Galmed Pharmaceuticals Ltd Stock Analysis and ForecastResistance Breakout Alerts & Rapid Wealth Accumulation - earlytimes.in
Why Galmed Pharmaceuticals Ltd. stock is trending among retail traders2025 Volatility Report & AI Driven Stock Movement Reports - newser.com
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):